<DOC>
	<DOCNO>NCT00003673</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness CMA-676 treating old patient acute myeloid leukemia recur first time follow least 3 month complete remission .</brief_summary>
	<brief_title>CMA-676 Treating Older Patients With Acute Myeloid Leukemia First Relapse</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy CMA-676 elderly patient acute myeloid leukemia first relapse term number patient attain complete remission . II . Assess safety CMA-676 patient population . OUTLINE : This open label , single arm , multicenter study . Patients receive 1 course CMA-676 IV 2 hour day 1 follow 6 hour observation period . Patients may receive 1 additional course therapy 15 28 day later . There 28 day follow-up period last dose study medication . Patients follow additional 6 month , every 3 month 18 month , every 6 month relapse and/or death . PROJECTED ACCRUAL : A total 23-55 patient accrue study within 12 month . Enrollment extend additional 55 patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : CD33 positive acute myeloid leukemia first relapse At least 3 month complete remission No history secondary leukemia evolve know prior myelodysplastic syndrome result exposure chemotherapy toxins No active CNS leukemia PATIENT CHARACTERISTICS : Age : 60 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC le 30,000/mm3 time CMA676 administration Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 3.0 mg/dL Cardiovascular : No uncontrolled cardiac disease Pulmonary : No uncontrolled pulmonary disease Other : No active malignancy No uncontrolled , lifethreatening infection Able obtain bone marrow aspirate HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell transplantation No prior antiCD33 antibody therapy Chemotherapy : Prior cytotoxic chemotherapy AML allow No prior chemotherapy AML first relapse except hydroxyurea At least 24 hour since prior hydroxyurea Recovered prior antineoplastic therapy ( except alopecia ) No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent immunosuppressive therapy Radiotherapy : Not specify Surgery : Not specify Other : At least 4 week since prior investigational agent No concurrent antileukemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>